• Qatar's largest IVF institution, Hamad Medical Corporation (HMC), has commenced commercial ordering of Felix™ cartridges
• Initial HMC demand tracking at approximately 100 Felix™ cartridges per month, supporting ~1,500 IVF cycles per annum
• Separate follow-on order for a further 200 Felix™ cartridges secured by ITL, reflecting broader MENA clinic demand outside Qatar

Memphasys Limited (ASX: MEM) ('Memphasys' or 'the Company') is pleased to confirm that Hamad Medical Corporation (HMC), one of Qatar's largest and most prominent fertility providers, has committed to commencing commercial in-clinic use of the Felix™ system, including ongoing orders of Felix™ cartridges given that CE-Mark approval allows for the immediate use of Felix in the country. This represents a significant milestone in the Company's Middle East and North Africa (MENA) commercial rollout. The commitment from HMC is a direct result of Memphasys' go-direct commercial strategy, executed in partnership with International Technical Legacy (ITL), and provides strong and rapid validation of Felix™'s clinical value proposition and the effectiveness of this approach in accelerating adoption across the region. HMC, Qatar's primary public health provider and leading reproductive medicine service, conducts approximately 1,500 fresh Assited Reproductive Technology (ART) cycles annually and has begun adopting Felix™ at an initial rate of around 100 cartridges per month, establishing a strong recurring institutional demand profile. With an initial annual usage of 1,200 cartridges, HMC alone accounts for almost half ITL's minimum annual contractual commitment of 2500 cartridges, providing early confirmation of contracted demand. Separately, and reflecting broader clinic demand across the MENA region, Memphasys has secured a follow-on order for a further 200 Felix™ cartridges under its distribution agreement with International Technical Legacy (ITL). This follow-on order is not specific to HMC, and reflects increasing procurement activity across ITL's regional clinic network including the United Arab Emirates, conversion of post-CE Mark interest into commercial purchasing, and growing confidence in Felix™ across multiple IVF operators. Together, the HMC deployment and the ITL follow-on order demonstrate both institutional adoption and wider regional demand for Felix™. Further, ITL/MEM are finalising several late stage contractual discussions with clients located across five (5) other countries, which the Company is confident of finalising in the coming months.

With institutional adoption underway at Hamad Medical Corporation, additional cartridge orders secured through ITL, and expanding engagement across Egypt and the broader MENA region, Memphasys believes Felix™ is entering a new phase of commercial execution in the Middle East & North Africa, underpinned by both anchor-customer validation and growing regional demand.